Jama Neurology Releases Highly Promising Data From ALS Clinical Trial Conducted By Hadassah Medical Organization Jerusalem And Brainstorm Cell Therapeutics

NEW YORK ­– A new ALS treatment utilizing a stem cell infusion protocol performed at Hadassah Medical Organization (HMO) and developed by the US/Israeli biotech company BrainStorm Cell Therapeutics (NASDAQ: BCLI), has significantly slowed the progression of Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's Disease), announced Ellen Hershkin, National President of Hadassah, the Women's Zionist Organization of America, Inc. (HWZOA). 

JAMA Neurology published the findings of the Phase 1/2 and Phase 2a ALS Clinical Trials conducted by Dr. Dimitrios Karussis, MD, PhD, Sr. Neurologist, HMO Neurology, in their 1/11/16 issue.  These Clinical Trials, which began in 2011, utilized an innovative adult stem cell self-transplantation treatment involving the harvesting of stem cells from the patient's bone marrow, their culture and enhancement using Brainstorm's patented protocol NurOwn® and their injection into the patient's cerebrospinal fluid by a technique that was developed and proposed by the Hadassah investigators.  26 ALS patients participated in the trials at HMO / Jerusalem, which is owned by HWZOA.  

HMO Principal Investigator Dr. Karussis explains the JAMA Neurology study findings: "The results are very encouraging.  Close to 90percent of patients who were injected intrathecally through the spinal cord fluid were regarded as responders to the treatment either in terms of their respiratory function or their motor disability.  Almost all of the patients injected in this way showed less progression and some even improved in their respiratory functions or their motor functions.  A Phase 2, double blind, study is running currently, at Mayo Clinic, Massachusetts General Hospital and University of Massachusetts Memorial Medical Center, using a treatment protocol identical to the HMO trial.  

Dr. Karussis continued, "In 2011, BrainStorm Cell Therapeutics initiated a Phase 1/2 clinical trial with ALS patients who received NurOwn™ cells. The trial, which was conducted at the Hadassah Medical Organization in Jerusalem, was designed to primarily evaluate the safety and tolerability of NurOwn™ in ALS patients. In two open-label studies, intrathecal (IT) or intramuscular (IM) treatment of 26 ALS patients with autologous MSC-NTF cells was found to be safe and well-tolerated over the study period.  Our data also provide clear indications for clinically meaningful beneficial effects. I am optimistic that within the foreseeable future, we may provide a treatment to ALS patients that can slow down or stop the progression. I believe we are in the early stages of something new and revolutionary with this harvested stem cell infusion therapy.  While this is absolutely by no means a cure, it is the first step in a long process in that direction.  I see this treatment as being potentially one of the major future tools to treat degenerative diseases of the brain and spinal cord, in general."  

The JAMA Neurology study also details NurOwn,® BrainStorm's proprietary process for differentiation of autologous Mesenchymal Stem Cells (MSC) into NeuroTrophic Factor (NTF)-secreting cells (MSC-NTF), and their transplantation back into the ALS patient at or near the site of damage.  These specialized adult stem cells, derived from the patient's own bone marrow, deliver nerve growth factors directly into the affected tissue sites in order to enhance the growth and function of the nerve cells. The ability to induce differentiation of autologous adult Mesenchymal Stem Cells into MSC-NTF cells is unique to NurOwn® making it the first-of-its-kind treatment for treating neurodegenerative diseases. The activity and potency of these stem cells is validated before transplantation.  

NurOwn® received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in February, 2011, and from the European Commission in July 2013. In October, 2014 Brainstorm was granted Fast Track designation for NurOwn® by the FDA.  A 2011 study determined that BrainStorm's self-transplantation approach has a high safety profile, with no risk of rejection and no need for treatment with immunosuppressive agents which can cause severe and/or long-term side effects. 

Hadassah President Ellen Hershkin states, "For over 75 years, Hadassah's hospitals have been in the vanguard of innovative medical discoveries, research and treatments. Under Dr. Karussis' direction, HMO is eager to continue its groundbreaking work to combat ALS and similar neurodegenerative or neuroinflammatory diseases, such as multiple sclerosis and many others.  ALS is estimated to affect 30,000 people in the US and 450,000 worldwide."   

Chaim Lebovits, President of BrainStorm Cell Therapeutics, states, "BrainStorm Cell Therapeutics, a leading developer of stem cell technologies for neurodegenerative diseases, is proud to be a pioneer in the testing and development of stem cell transplantation treatments for ALS. Following the spectacular results of our 2nd Phase trials, BrainStorm looks forward to the results of the US double blind trial as well as the start of a multiple dose trial at HMO in Israel to help us prove the efficacy of this innovative new treatment." 

More in Research

Research  Jan 19

NIH Genome Sequencing Program Targets the Genomic Bases of Common, Rare Disease

The National Institutes of Health will fund a set of genome sequencing and analysis centers whose research will focus on understanding…

Research  Jan 15

Social Media May Provide Key Health Information

Could your Facebook posts be the clue to your health?

Research  Jan 15

Mercy Offers a Nationwide Cancer Trial

Could chemotherapy become a thing of the past?

Research  Jan 06

Findings on Fat Cell Metabolism

A new study shows simple sugars are not the only favored nutrient of fat cells.

Clinical  Jan 06

A Clearer Picture: Imaging Rhodopsin Could Shed Light on Retinal Disorders

A new retinal imaging technology holds the promise of improved diagnostics, assessment of vision loss, and effectiveness of therapy.

Research  Jan 01

Special Report on the Future of Cancer Prevention Research Published in American Association for Cancer Research Journal

PHILADELPHIA — A special report that sets out a brief agenda for the immediate future of cancer prevention research was published…

Research  Dec 15

Five Factors Identify Subset of Patients With Advanced Cervical Cancer Who May Not Benefit From Bevacizumab Treatment

New study prospectively validated the five prognostic factors called the Moore criteria.

Clinical  Dec 11

Statin Therapy Benefits Patients with Highest Genetic Risk of Heart Attack

Which patients benefit the most from statins?

Clinical  Nov 01

Nanotechnology Meeting its Potential

NCSU engineer develops joint replacements containing nanotechnology to combat post-surgical infections.

Research  Oct 06

BreastCancerTrials.org Launches Metastatic Trial Search

Non-profit clinical trial matching service partners with leading breast cancer advocacy groups to make details about metastatic…

Feature Profiles  Oct 01

Half-match Stem-cell Transplant Program Leads to Lifesaving Option

As director of the Haploidentical Transplant Program at Washington University School of Medicine, Rizwan Romee, MD, is pioneering new…

Research  Sep 14

Using Deep Brain Stimulation to Treat OCD Patients

Does Deep Brain Stimulation Provide Cure for OCD?

Research  Sep 11

PanCAN, AACR Call for 2016 Research Grant Applications

The Pancreatic Cancer Action Network and American Association for Cancer Research invite early career investigators to submit 2016 research grant applications by noon (ET) on Oct. 8 (Career Development Awards) or Oct. 27 Pathway to Leadership Grant).

Clinical  Sep 02

No Relief for Allergy Sufferers

Allergy cases are on the rise everywhere.

Home  Sep 02

Saint Louis University Hospital Makes Recovery Easier with Catheter-Less Prostatectomy

Who in St. Louis is offering catheter-less prostatectomy?

Research  Aug 31

New Down Syndrome Discovery

Researchers target chromosome disorders with natural chromosome therapy

Research  Aug 14

AHA Scientific Statement: Mobile Technology May Help People Improve Health Behaviors

Preliminary data suggest that smart phone apps and wearable sensors are promising for improving cardiovascular health behaviors.

Business  Aug 12

Siteman Receives Highest Possible NCI Rating

Cancer Center at Barnes-Jewish and Wash U Stands with Nation’s Elite

Research  Jul 24

Landmark Global Study Provides New Evidence of Lymph Node Radiation Benefit in Long-Term Breast Cancer Control

An Australian/North American clinical trial has shown significant improvement in cancer-free survival among women who underwent lymph node radiation when their breast cancer that had spread to the lymph nodes.

Research  Jul 16

Small, New Study Shows More than Half of Breast Cancer Patients Develop Diastolic Dysfunction After Anthracycline-Based Chemotherapy

Patients who undergo treatment with anthracycline-based chemotherapy for breast cancer are at risk of developing diastolic dysfunction, according to a new study published in The Oncologist on July 16, 2015. Within 12 months of completing anthracycline…

Research  Jul 15

New CDC Study Highlights Pneumonia Hospitalizations Among U.S. Adults

Viruses, not bacteria, are the most commonly detected respiratory pathogens in U.S. adults hospitalized with pneumonia, according to a New England Journal of Medicine study released in mid-July and conducted by researchers at Centers for Disease Control…

  Load more content